

AXIRON[®] LAUNCHED IN CANADA

Acrux (ASX: ACR) today confirmed that Axiron[®] is now being distributed by Eli Lilly in Canada for testosterone replacement therapy in men for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).

Acrux Executive Chairman Ross Dobinson commented “We are pleased that Lilly has achieved another planned milestone in the international commercialisation of Axiron, which is now available to patients in the United States, Australia and Canada”.

Contact

Ross Dobinson, Executive Chairman: 0418 347 494

About Acrux

Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative liquid technology to administer drugs through the skin. Acrux has products marketed by licensees in the United States, Europe, Australia and Canada, and in registration or development.